Is NAD+ a Peptide? No — and the Mix-Up Costs Money

No. NAD+ is not a peptide, and it does not contain a single amino acid. It is a dinucleotide — two nucleotides, nicotinamide mononucleotide and adenosine monophosphate, joined tail-to-tail through a pyrophosphate bridge. A peptide is something else entirely: a short chain of amino acids strung together by peptide bonds. The two molecule classes share no building blocks, no chemistry, and no mechanism.

So why does the question get asked thousands of times a month? Because of where NAD+ is sold. Walk through the menu of almost any compounding-pharmacy telehealth service and NAD+ sits in a numbered list between BPC-157 and sermorelin, drawn from an identical vial, reconstituted with the same bacteriostatic water, and injected with the same insulin syringe. Clinics label the whole shelf "peptide therapy." The packaging is identical, so the categories blur.

That blur is not harmless, and it is the reason this page exists. Calling NAD+ a peptide quietly imports a body of evidence that belongs to other molecules — and the evidence NAD+ injections actually have is far thinner than the shelf they sit on implies.

What a peptide actually is

Peptides are chains of amino acids linked by peptide bonds — the same bond type that builds proteins, just at a shorter length. The boundary between "peptide" and "protein" is conventional rather than sharp, but the working definition in drug discovery is roughly two to fifty amino acids ¹.

That structure is what gives peptide drugs their behaviour. Because they are built from amino acids, they fold into shapes that fit receptors with high specificity, and because they are built from amino acids, digestive enzymes shred them — which is why most peptide drugs are injected rather than swallowed. Over eighty peptide drugs have reached the market, including insulin, the GLP-1 agonists, and the GHRH analogue sermorelin ¹.

Note what that list has in common: each one is an amino-acid chain that binds a specific receptor. That is the category.

What NAD+ actually is

NAD+ (nicotinamide adenine dinucleotide) is not in that category. It is a coenzyme — a small helper molecule that enzymes borrow to do chemistry, present in every living cell.

Structurally it is two nucleotides joined at the phosphates: nicotinamide mononucleotide on one side, adenosine monophosphate on the other. Each of those halves consists of a nitrogenous base, a ribose sugar and a phosphate group. Amino acids appear nowhere in the molecule, and neither does a peptide bond.

Functionally it does two jobs. It carries electrons — cycling between NAD+ and NADH as it shuttles reducing power through the reactions that turn food into ATP. And it is consumed as a substrate by a set of enzymes, including the sirtuins, PARPs and CD38, which cleave it apart to do their work. Those enzymes sit at the centre of DNA repair, metabolic signalling and the biology of ageing, which is why NAD+ became a longevity target in the first place ². Human tissue studies have documented that NAD+ falls with age alongside rising oxidative stress ³, and that decline is the entire rationale behind "NAD+ restoration."

A peptide binds a receptor to send a signal. NAD+ is a chemical currency that enzymes spend. Those are different jobs, and no amount of shared shelf space makes them the same one.

Why the mix-up matters commercially

If this were purely a nomenclature question, it would be a pedantic one. It isn't, for a specific reason: the "peptide therapy" frame carries an evidence halo that NAD+ injections have not earned.

Some genuine peptide drugs have decades of trials and FDA approvals behind them. Insulin and the GLP-1 agonists are peptides with enormous outcome datasets. When a clinic files NAD+ under the same heading, a reader reasonably assumes the category's credibility transfers.

It does not. There is no published randomized controlled trial showing that injected NAD+ improves energy, focus, recovery, or any ageing-related outcome — and there is not even a published pharmacokinetic study of the subcutaneous or intramuscular route. The only human data on putting NAD+ directly into the body is a single 2019 pilot that tracked the plasma and urine NAD+ metabolome during a six-hour intravenous infusion, and found free NAD+ largely undetectable in blood for hours as the body metabolised it ⁴. That study measured biochemistry, not whether anyone felt better. We go through the whole injectable literature in our NAD+ injections evidence review.

Meanwhile the parts of this category that do have human trials are the cheap oral ones. Nicotinamide riboside has formal ascending-dose pharmacokinetics in humans and raises blood NAD+ predictably ⁵. Oral NMN has a randomized, placebo-controlled dose-finding trial at 300, 600 and 900 mg/day ⁶. And even those honest trials keep landing on the same uncomfortable result — raising the biomarker does not reliably change how people feel. NR augmented the aged human muscle NAD+ metabolome without improving muscle bioenergetics or physical performance ⁷. The clearest positive human signal in the whole field is narrow: oral NMN improved muscle insulin sensitivity in prediabetic women ⁸, a specific endpoint in a specific population.

So the ranking runs opposite to the pricing. The best-evidenced thing here is a capsule that costs a few dollars a day; the least-evidenced is the injection filed under "peptides" at several hundred dollars a month. A comprehensive review of NAD-boosting molecules made the same point years ago — the preclinical case is genuinely exciting and the human outcome evidence has not caught up with it ⁹.

"NAD+ peptide injection" — what people mean when they search it

The phrase is common enough that it deserves a direct answer rather than a correction. Someone searching "NAD+ peptide injection" is almost never asking a chemistry question. They are asking about a specific product: a compounded NAD+ vial, sold by a peptide-focused telehealth clinic, self-injected subcutaneously at home.

That product is real and you can buy it today. It is simply not a peptide, and the two things worth knowing about it are unaffected by the label:

• •It is compounded, not FDA-approved. Strength, sterility and labelling depend on the compounding pharmacy that filled it — which is why the pharmacy behind a provider matters more than its branding.
• •The dose is not trial-derived. No study has established a subcutaneous NAD+ dose, so the tidy charts online are clinic marketing rather than pharmacology. If you already have a prescriber's protocol and need to turn milligrams into syringe units, our NAD+ injection dosage calculator does that arithmetic without pretending to set the dose.

Is NMN a peptide? Is NR? Same answer

The correction extends cleanly to the precursors, which get the same treatment on the same menus:

• •NMN (nicotinamide mononucleotide) is a mononucleotide — one nitrogenous base, one ribose, one phosphate. Half of an NAD+ molecule, structurally. Not a peptide.
• •NR (nicotinamide riboside) is a nucleoside — a base plus a sugar, no phosphate. Not a peptide.
• •Niacin and nicotinamide are forms of vitamin B3. Not peptides either.

Every molecule in the NAD+ family tree is built from nucleotide parts. None of them contains an amino acid. We compare the two most-sold precursors directly in NMN vs NR, and untangle NMN from NAD+ itself in NMN vs NAD+.

Sermorelin, BPC-157, ipamorelin and tesamorelin — the molecules NAD+ sits beside on those menus — are genuine peptides. The shelf contains both categories. It is only the heading that is wrong.

The one-line answer

NAD+ is a dinucleotide coenzyme, not a peptide: no amino acids, no peptide bonds, no receptor to bind. It ended up under the "peptide therapy" banner because compounding clinics sell it from the same vials, on the same menus, through the same syringes as the actual peptides — a marketing adjacency, not a chemical one.

Knowing the difference is worth something concrete. It stops you crediting an injectable NAD+ protocol with evidence that belongs to insulin and the GLP-1 drugs, and it points you at the real question, which is not what class is this molecule but which route has ever been tested in humans. On that question the answer is uncomfortable and consistent: the oral precursors have the trials, the injections have the price tag. Work through it in is NAD+ therapy worth it?, compare the routes head to head in NAD+ IV vs injection vs oral, and if you have decided to buy anyway, compare what providers actually charge on our NAD+ rankings hub.